Identification and Characterisation of 2-Aminopyridine Inhibitors of Checkpoint Kinase 2
Hilton, S., Naud, S., Caldwell, J.J., Boxall, K., Burns, S., Anderson, V.E., Antoni, L., Allen, C.E., Pearl, L.H., Oliver, A.W., Aherne, G.W., Garrett, M.D., Collins, I.(2010) Bioorg Med Chem 18: 707
- PubMed: 20022510 
- DOI: https://doi.org/10.1016/j.bmc.2009.11.058
- Primary Citation of Related Structures:  
2WTC, 2WTD, 2WTI, 2WTJ - PubMed Abstract: 
5-(Hetero)aryl-3-(4-carboxamidophenyl)-2-aminopyridine inhibitors of CHK2 were identified from high throughput screening of a kinase-focussed compound library. Rapid exploration of the hits through straightforward chemistry established structure-activity relationships and a proposed ATP-competitive binding mode which was verified by X-ray crystallography of several analogues bound to CHK2. Variation of the 5-(hetero)aryl substituent identified bicyclic dioxolane and dioxane groups which improved the affinity and the selectivity of the compounds for CHK2 versus CHK1. The 3-(4-carboxamidophenyl) substituent could be successfully replaced by acyclic omega-aminoalkylamides, which made additional polar interactions within the binding site and led to more potent inhibitors of CHK2. Compounds from this series showed activity in cell-based mechanistic assays for inhibition of CHK2.
Organizational Affiliation: 
Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.